A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Launched by HANMI PHARMACEUTICAL COMPANY LIMITED · Dec 12, 2017
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
A First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Female subjects must be non-pregnant and non-lactating
- Exclusion Criteria:
- • Participation in an investigational study within 30 days prior to dosing
About Hanmi Pharmaceutical Company Limited
Hanmi Pharmaceutical Company Limited is a leading South Korean biopharmaceutical firm dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a strong focus on addressing unmet medical needs, Hanmi leverages advanced technologies and a robust pipeline of drug candidates across various therapeutic areas, including oncology, diabetes, and autoimmune diseases. The company emphasizes collaboration and strategic partnerships to enhance its research capabilities and accelerate the development of novel treatments, positioning itself as a key player in the global healthcare landscape. Hanmi's commitment to quality, safety, and efficacy underpins its clinical trials, ensuring rigorous adherence to regulatory standards and contributing to the advancement of patient care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chula Vista, California, United States
Patients applied
Trial Officials
Hanmi Pharmaceuticals
Study Director
Hanmi Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials